MX2010002909A - Metodo de tratamiento de pacientes de hepatitis c. - Google Patents
Metodo de tratamiento de pacientes de hepatitis c.Info
- Publication number
- MX2010002909A MX2010002909A MX2010002909A MX2010002909A MX2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A MX 2010002909 A MX2010002909 A MX 2010002909A
- Authority
- MX
- Mexico
- Prior art keywords
- patients
- treatment
- treating hepatitis
- naã
- hcv infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Esta solicitud describe un método novedoso de identificación de pacientes, entre pacientes nuevos en el tratamiento que padecen infección de VHC, que son susceptibles de tratamiento con un inhibidor de proteasa; la solicitud también describe un método de tratamiento de pacientes nuevos en el tratamiento, pacientes no respondedores y pacientes en recaída que padecen una infección de VHC.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99375307P | 2007-09-14 | 2007-09-14 | |
US99876207P | 2007-10-12 | 2007-10-12 | |
US149407P | 2007-10-30 | 2007-10-30 | |
PCT/US2008/010626 WO2009038663A1 (en) | 2007-09-14 | 2008-09-11 | Method of treating hepatitis c patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010002909A true MX2010002909A (es) | 2010-03-30 |
Family
ID=40262964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010002909A MX2010002909A (es) | 2007-09-14 | 2008-09-11 | Metodo de tratamiento de pacientes de hepatitis c. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100226885A1 (es) |
EP (2) | EP2061513B1 (es) |
JP (1) | JP2010539165A (es) |
CN (1) | CN101883590A (es) |
AT (1) | ATE519503T1 (es) |
AU (1) | AU2008301981A1 (es) |
CA (1) | CA2699280A1 (es) |
CY (1) | CY1112116T1 (es) |
DK (1) | DK2061513T3 (es) |
ES (1) | ES2369321T3 (es) |
HK (1) | HK1129315A1 (es) |
HR (1) | HRP20110637T1 (es) |
MX (1) | MX2010002909A (es) |
NZ (1) | NZ583825A (es) |
PL (1) | PL2061513T3 (es) |
PT (1) | PT2061513E (es) |
SI (1) | SI2061513T1 (es) |
WO (1) | WO2009038663A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
EP2704570A4 (en) * | 2011-05-04 | 2015-02-18 | Merck Sharp & Dohme | ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
AU2012332827A1 (en) | 2011-10-31 | 2014-05-15 | Gilead Pharmasset Llc | Methods and compositions for treating hepatitis C virus |
AU2012346217B2 (en) * | 2011-11-29 | 2016-02-04 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013116592A1 (en) | 2012-02-01 | 2013-08-08 | Kadmon Pharmaceuticals, Llc | Once daily treatment of hepatitis c with ribavirin and taribavirin |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037110A2 (en) * | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
WO2000051631A2 (en) * | 1999-03-02 | 2000-09-08 | Schering Corporation | Pegylated alpha interferon for hiv therapy |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
PT1730110E (pt) | 2004-02-27 | 2010-09-14 | Schering Corp | Compostos de enxofre como inibidores de serina-protease ns3 do vírus da hepatite c |
WO2006016930A2 (en) * | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
WO2006130553A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
US20070274951A1 (en) | 2006-02-09 | 2007-11-29 | Xiao Tong | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto |
AU2009256623A1 (en) * | 2008-06-10 | 2009-12-17 | Janssen Pharmaceutica Nv | Telaprevir dosing regimen |
-
2008
- 2008-09-11 CA CA2699280A patent/CA2699280A1/en not_active Abandoned
- 2008-09-11 AU AU2008301981A patent/AU2008301981A1/en not_active Abandoned
- 2008-09-11 MX MX2010002909A patent/MX2010002909A/es not_active Application Discontinuation
- 2008-09-11 WO PCT/US2008/010626 patent/WO2009038663A1/en active Application Filing
- 2008-09-11 PT PT08831728T patent/PT2061513E/pt unknown
- 2008-09-11 AT AT08831728T patent/ATE519503T1/de active
- 2008-09-11 US US12/376,180 patent/US20100226885A1/en not_active Abandoned
- 2008-09-11 NZ NZ583825A patent/NZ583825A/en not_active IP Right Cessation
- 2008-09-11 CN CN200880116595XA patent/CN101883590A/zh active Pending
- 2008-09-11 DK DK08831728.4T patent/DK2061513T3/da active
- 2008-09-11 JP JP2010524864A patent/JP2010539165A/ja active Pending
- 2008-09-11 SI SI200830406T patent/SI2061513T1/sl unknown
- 2008-09-11 EP EP08831728A patent/EP2061513B1/en not_active Revoked
- 2008-09-11 EP EP11176964A patent/EP2489369A1/en not_active Withdrawn
- 2008-09-11 ES ES08831728T patent/ES2369321T3/es active Active
- 2008-09-11 PL PL08831728T patent/PL2061513T3/pl unknown
-
2009
- 2009-09-14 HK HK09108390.0A patent/HK1129315A1/xx not_active IP Right Cessation
-
2011
- 2011-09-07 HR HR20110637T patent/HRP20110637T1/hr unknown
- 2011-11-01 CY CY20111101045T patent/CY1112116T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE519503T1 (de) | 2011-08-15 |
EP2489369A1 (en) | 2012-08-22 |
AU2008301981A1 (en) | 2009-03-26 |
PT2061513E (pt) | 2011-10-17 |
US20100226885A1 (en) | 2010-09-09 |
CA2699280A1 (en) | 2009-03-26 |
EP2061513B1 (en) | 2011-08-10 |
PL2061513T3 (pl) | 2011-12-30 |
CY1112116T1 (el) | 2015-11-04 |
SI2061513T1 (sl) | 2011-11-30 |
DK2061513T3 (da) | 2011-11-21 |
HRP20110637T1 (hr) | 2011-10-31 |
HK1129315A1 (en) | 2009-11-27 |
ES2369321T3 (es) | 2011-11-29 |
JP2010539165A (ja) | 2010-12-16 |
WO2009038663A1 (en) | 2009-03-26 |
CN101883590A (zh) | 2010-11-10 |
EP2061513A1 (en) | 2009-05-27 |
NZ583825A (en) | 2012-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010002909A (es) | Metodo de tratamiento de pacientes de hepatitis c. | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
MY177001A (en) | Phenothiazine compounds for treating mild cognitive impairment | |
MY165570A (en) | Inhibitors of poly (adp-ribose) polymerase | |
GEP20084545B (en) | Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection | |
TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
SG10201406297TA (en) | Methods for treating progressive multiple sclerosis | |
SG179488A1 (en) | Virus like particle purification | |
TN2010000137A1 (en) | Spiropyrrolidines and their use against hcv and hiv infection | |
MX2020009703A (es) | Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina. | |
DK1505990T3 (da) | Fremgangsmåder til behandling af hepatitis | |
GEP20166426B (en) | Pirfenidone therapy and inducers of cytochrome p450 | |
MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
MX2009007053A (es) | Inhibidores de poli (adp-ribosa) polimerasa. | |
UA88655C2 (ru) | S-миртазапин для лечения прилива крови | |
TW200507840A (en) | Method of treating multiple myeloma | |
WO2008092099A3 (en) | Compositions and methods for treating hematopoietic malignancies | |
MY152546A (en) | A non-reusable circumcision clamp | |
MX2009003022A (es) | Composiciones y metodos para tratar picaduras de medusa. | |
MX2013003903A (es) | Nuevos tratamientos de infeccion por el virus de hepatitis c. | |
MY166063A (en) | Intravenous antiviral treatments | |
TW200500585A (en) | Device and method for heat treatment | |
WO2008033368A3 (en) | Boroproline compound and cytokine combination therapy | |
UA29556U (ru) | Способ лечения больных острыми вирусными менингитами | |
UA35880U (ru) | Способ лечения острого токсико-аллергического гепатита |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: QLT INC. |
|
FA | Abandonment or withdrawal |